Subscribe
sdx15 / Shutterstock.com
28 July 2025NewsAmericasMarisa Woutersen

Novartis moves to block cancer drug generic in US

Swiss pharma giant files patent infringement lawsuit to stop Teva’s generic Mekinist launch in US | Follows European Patent Office revocation of key patent after Teva proved lack of inventive step.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novartis loses cancer drug patent following Teva challenge at EPO
24 June 2025   Appeals board overturns previous decision and revokes patent on treatment worth $2bn in 2024 | Teva and Generics UK successful in arguing lack of inventive step.


Editor's picks

BMS blocks biosimilar version of blockbuster cancer drug in India
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025

Editor's picks

Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

More on this story

Americas
Novartis loses cancer drug patent following Teva challenge at EPO
24 June 2025   Appeals board overturns previous decision and revokes patent on treatment worth $2bn in 2024 | Teva and Generics UK successful in arguing lack of inventive step.

More on this story

Americas
Novartis loses cancer drug patent following Teva challenge at EPO
24 June 2025   Appeals board overturns previous decision and revokes patent on treatment worth $2bn in 2024 | Teva and Generics UK successful in arguing lack of inventive step.

More features

WATCH: China patent landscape—AI, patent linkage, export controls, and more
China bars USPTO employee from leaving country
UPC hands rare default win to Insulet, bans insulin pump in EU
GSK loses appeal over purple inhaler TM in Europe
Astellas defends Xtandi patent as court rejects generics’ appeal
Jury sides with Allergan in $56M Botox tech feud
Novartis fails latest bid to block Entresto copies
BMS blocks biosimilar version of blockbuster cancer drug in India